我們已在上線! 進一步了解
ALMR圖示

Alamar Biosciences

25.28 USD
-2.14
7.8%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
25.28
0.00
0%
1天
-7.8%
5天
0.84%
1個月
-13.96%
3個月
1.32%
6個月
14.91%
今年迄今
14.91%
1年
14.91%
5年
14.91%
10年
14.91%
 

關於: Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.

新聞

正面
中性
負面
市場情緒 3個月
正面 33.3%
中性 66.7%
負面 0%
中性
GlobeNewsWire
8 天前
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
FREMONT, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the third quarter 2026 after market close on Tuesday, November 3, 2026.
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
正面
Seeking Alpha
8 天前
Alamar: The Consumables Flywheel Is Just Getting Started
Alamar Biosciences is rated a buy, targeting a recurring consumables-driven model with expansion into clinical diagnostics. 2Q26 revenue surged 82% YoY to $29.4M, with consumables up 147% and now exceeding half of total revenue. Gross margin improved to 60% on manufacturing efficiencies and consumables mix, but high operating expenses maintain losses amid aggressive investment.
Alamar: The Consumables Flywheel Is Just Getting Started
中性
GlobeNewsWire
11 天前
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
中性
GlobeNewsWire
22 天前
Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab
Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment
中性
Seeking Alpha
上個月
Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
中性
GlobeNewsWire
上個月
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
正面
Seeking Alpha
2 個月前
Alamar Biosciences: Promising But Expensive Proteomics Growth
Alamar Biosciences' ARGO instruments automate NULISA assays. This creates a platform that can convert placements into recurring consumables' demand. I concede that ALMR's broader disease panels and sampling could also deepen the utilization of its platform and expand its long-term TAM even into diagnostics. The good news is that consumables are growing faster than instruments. But we need to see if this will be long-term profitable growth as the installed base expands.
Alamar Biosciences: Promising But Expensive Proteomics Growth
正面
Seeking Alpha
2 個月前
Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument
Alamar Biosciences is building a content-driven proteomics platform, with accelerating consumables revenue and expanding biomarker panels driving long-term growth. Q2 2026 revenue grew 82% YoY to $29.4M, with consumables sales up 147% and gross margin rising to 60%, highlighting improving revenue quality and operational leverage potential. ALMR's installed base enables capital-efficient expansion, with new assays deployable across existing instruments, creating workflow stickiness and recurring revenue opportunities.
Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument
正面
Benzinga
2 個月前
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
Alamar Biosciences Inc. (NASDAQ:ALMR) shares are trading higher on Tuesday as the company is expanding its global partnership with the Alzheimer's Disease Data Initiative and Gates Ventures.
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
中性
Seeking Alpha
2 個月前
Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript
Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript
Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript
價格圖表採用Lightweight Charts™實作